Logo image of NKTX

NKARTA INC (NKTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NKTX - US65487U1088 - Common Stock

1.895 USD
+0.06 (+3.55%)
Last: 11/28/2025, 12:58:04 PM
Fundamental Rating

3

Overall NKTX gets a fundamental rating of 3 out of 10. We evaluated NKTX against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for NKTX as it has an excellent financial health rating, but there are worries on the profitability. NKTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NKTX had negative earnings in the past year.
In the past year NKTX has reported a negative cash flow from operations.
In the past 5 years NKTX always reported negative net income.
In the past 5 years NKTX always reported negative operating cash flow.
NKTX Yearly Net Income VS EBIT VS OCF VS FCFNKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of NKTX (-24.02%) is better than 72.80% of its industry peers.
NKTX's Return On Equity of -30.37% is fine compared to the rest of the industry. NKTX outperforms 77.30% of its industry peers.
Industry RankSector Rank
ROA -24.02%
ROE -30.37%
ROIC N/A
ROA(3y)-25.65%
ROA(5y)-27.09%
ROE(3y)-33.49%
ROE(5y)-32.64%
ROIC(3y)N/A
ROIC(5y)N/A
NKTX Yearly ROA, ROE, ROICNKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

NKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NKTX Yearly Profit, Operating, Gross MarginsNKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

7

2. Health

2.1 Basic Checks

NKTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NKTX has more shares outstanding
There is no outstanding debt for NKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NKTX Yearly Shares OutstandingNKTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NKTX Yearly Total Debt VS Total AssetsNKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -1.34, we must say that NKTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.34, NKTX is in line with its industry, outperforming 54.97% of the companies in the same industry.
There is no outstanding debt for NKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.34
ROIC/WACCN/A
WACCN/A
NKTX Yearly LT Debt VS Equity VS FCFNKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

NKTX has a Current Ratio of 15.23. This indicates that NKTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NKTX (15.23) is better than 92.31% of its industry peers.
A Quick Ratio of 15.23 indicates that NKTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 15.23, NKTX belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.23
Quick Ratio 15.23
NKTX Yearly Current Assets VS Current LiabilitesNKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.60% over the past year.
EPS 1Y (TTM)26.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NKTX will show a small growth in Earnings Per Share. The EPS will grow by 7.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.02%
EPS Next 2Y8.53%
EPS Next 3Y0.56%
EPS Next 5Y7.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NKTX Yearly Revenue VS EstimatesNKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
NKTX Yearly EPS VS EstimatesNKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTX. In the last year negative earnings were reported.
Also next year NKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTX Price Earnings VS Forward Price EarningsNKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTX Per share dataNKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.53%
EPS Next 3Y0.56%

More info and screens

0

5. Dividend

5.1 Amount

NKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NKARTA INC

NASDAQ:NKTX (11/28/2025, 12:58:04 PM)

1.895

+0.06 (+3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)05-12 2026-05-12
Inst Owners86.36%
Inst Owner Change-7.4%
Ins Owners0.4%
Ins Owner Change-0.05%
Market Cap134.58M
Revenue(TTM)N/A
Net Income(TTM)-102.61M
Analysts83.08
Price Target12.04 (535.36%)
Short Float %13.47%
Short Ratio9.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.82%
Min EPS beat(2)9.26%
Max EPS beat(2)14.39%
EPS beat(4)4
Avg EPS beat(4)11.18%
Min EPS beat(4)4.19%
Max EPS beat(4)16.89%
EPS beat(8)6
Avg EPS beat(8)8.7%
EPS beat(12)9
Avg EPS beat(12)9.62%
EPS beat(16)11
Avg EPS beat(16)8.65%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.84%
PT rev (3m)-4.84%
EPS NQ rev (1m)-2.69%
EPS NQ rev (3m)-2.69%
EPS NY rev (1m)0%
EPS NY rev (3m)1.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS4.76
TBVpS4.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.02%
ROE -30.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.65%
ROA(5y)-27.09%
ROE(3y)-33.49%
ROE(5y)-32.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.98%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.23
Quick Ratio 15.23
Altman-Z -1.34
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)770.74%
Cap/Depr(5y)709.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.64%
EPS Next Y16.02%
EPS Next 2Y8.53%
EPS Next 3Y0.56%
EPS Next 5Y7.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y4.08%
EBIT Next 5Y2.85%
FCF growth 1Y26.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.89%
OCF growth 3YN/A
OCF growth 5YN/A

NKARTA INC / NKTX FAQ

What is the ChartMill fundamental rating of NKARTA INC (NKTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NKTX.


Can you provide the valuation status for NKARTA INC?

ChartMill assigns a valuation rating of 0 / 10 to NKARTA INC (NKTX). This can be considered as Overvalued.


How profitable is NKARTA INC (NKTX) stock?

NKARTA INC (NKTX) has a profitability rating of 1 / 10.


Can you provide the financial health for NKTX stock?

The financial health rating of NKARTA INC (NKTX) is 7 / 10.